PLEXXIKON Trademark

Trademark Overview


On Friday, June 23, 2017, a trademark application was filed for PLEXXIKON with the United States Patent and Trademark Office. The USPTO has given the PLEXXIKON trademark a serial number of 87502726. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, August 9, 2024. This trademark is owned by Plexxikon Inc.. The PLEXXIKON trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for the treatment of cancer, diabetes, and central nervous system, autoimmune, bone, metabolic, and blood disorders

* Pharmaceutical * product [ development ] research, * pharmaceutical * product development, and * pharmaceutical * product * research and * development consultation regarding pharmaceutical [, biological and biotechnological ] products; [ Pharmaceutical research and development services; ] medical research and development services * for pharmaceuticals * in the field of treatments for cancer, diabetes, [ and central nervous system, ] autoimmune, bone, metabolic, and blood disorders; * none of the above including diagnostic services or products or reagents *
plexxikon

General Information


Serial Number87502726
Word MarkPLEXXIKON
Filing DateFriday, June 23, 2017
Status710 - CANCELLED - SECTION 8
Status DateFriday, August 9, 2024
Registration Number5390877
Registration DateTuesday, January 30, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 14, 2017

Trademark Statements


Amendment to a Registration/Renewal CertificateIn the statement of goods, Class 42 Product development research, product development, and product development consultation regarding pharmaceutical, biological and biotechnological products; Pharmaceutical research and development services; medical research and development services in the field of treatments for cancer, diabetes, and central nervous system, autoimmune, bone, metabolic, and blood disorders is deleted and "Pharmaceutical product research, pharmaceutical product development, and pharmaceutical product research and development consultation regarding pharmaceutical products; medical research and development services for pharmaceuticals in the field of treatments for cancer, diabetes, autoimmune, bone, metabolic, and blood disorders; none of the above including diagnostic services or products or reagents" is inserted.
Goods and ServicesPharmaceutical preparations for the treatment of cancer, diabetes, and central nervous system, autoimmune, bone, metabolic, and blood disorders
Goods and Services* Pharmaceutical * product [ development ] research, * pharmaceutical * product development, and * pharmaceutical * product * research and * development consultation regarding pharmaceutical [, biological and biotechnological ] products; [ Pharmaceutical research and development services; ] medical research and development services * for pharmaceuticals * in the field of treatments for cancer, diabetes, [ and central nervous system, ] autoimmune, bone, metabolic, and blood disorders; * none of the above including diagnostic services or products or reagents *

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, August 9, 2024
Primary Code005
First Use Anywhere DateMonday, December 22, 2003
First Use In Commerce DateMonday, December 22, 2003

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, August 9, 2024
Primary Code042
First Use Anywhere DateWednesday, April 30, 2003
First Use In Commerce DateWednesday, April 30, 2003

Trademark Owner History


Party NamePlexxikon Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBerkeley, CA 94710

Party NamePlexxikon Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBerkeley, CA 94710

Party NamePlexxikon Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBerkeley, CA 94710

Trademark Events


Event DateEvent Description
Friday, September 22, 2017EXAMINERS AMENDMENT -WRITTEN
Tuesday, June 27, 2017NEW APPLICATION ENTERED
Friday, June 30, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, September 21, 2017ASSIGNED TO EXAMINER
Friday, September 22, 2017EXAMINER'S AMENDMENT ENTERED
Friday, September 22, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, September 22, 2017EXAMINERS AMENDMENT E-MAILED
Friday, September 22, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, October 9, 2017ASSIGNED TO LIE
Wednesday, October 25, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 14, 2017PUBLISHED FOR OPPOSITION
Tuesday, November 14, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 30, 2018REGISTERED-PRINCIPAL REGISTER
Tuesday, May 1, 2018CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, April 12, 2018TEAS SECTION 7 REQUEST RECEIVED
Tuesday, May 1, 2018AMENDMENT UNDER SECTION 7 - PROCESSED
Thursday, March 7, 2019CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, March 7, 2019POST REGISTRATION ACTION CORRECTION
Friday, March 15, 2019AMENDMENT UNDER SECTION 7 - PROCESSED
Friday, April 15, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, April 15, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, April 15, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, January 30, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, August 9, 2024CANCELLED SEC. 8 (6-YR)